Sensitive quantification of IGF-1 and its synthetic analogs in dried blood spots

Bioanalysis

Volumn 6, Issue 19, 2014, Pages 2651-2662

  Cox, Holly D ^a   Hughes, Cole M ^a   Eichner, Daniel ^a  

^a Sports Medicine Research and Testing Laboratory   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE; HEMOGLOBIN; SOMATOMEDIN C DERIVATIVE; TRYPSIN; SOMATOMEDIN C;

ALKYLATION; AMINO ACID SEQUENCE; ARTICLE; CONTROLLED STUDY; DRIED BLOOD SPOT TESTING; FEMALE; HEMATOCRIT; HUMAN; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MEASUREMENT ACCURACY; MEASUREMENT PRECISION; NONHUMAN; PRICK TEST; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN DETERMINATION; PROTEIN STABILITY; RAT; SENSITIVITY AND SPECIFICITY; CHEMISTRY; PROCEDURES;

CHROMATOGRAPHY, LIQUID; DRIED BLOOD SPOT TESTING; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MASS SPECTROMETRY;

EID: 84913586836     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.14.109     Document Type: Article

References (33)

1. Fintini D, Brufani C, Cappa M. Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency. Ther. Clin. Risk Manag. 5(3), 553-559 (2009).
2. Bastian SE, Walton PE, Wallace JC, Ballard FJ. Plasma clearance and tissue distribution of labelled insulin-like growth factor-I (IGF-I) and an analogue LR3IGF-I in pregnant rats. J. Endocrinol. 138(2), 327-336 (1993).
3. Kohler M, Thomas A, Walpurgis K, Terlouw K, Schanzer W, Thevis M. Detection of His-tagged Long-R(3)-IGF-I in a black market product. Growth Horm. IGF Res. 20(5), 386-390 (2010).
4. Bredehoft M, Schanzer W, Thevis M. Quantification of human insulin-like growth factor-1 and qualitative detection of its analogues in plasma using liquid chromatography/electrospray ionisation tandem mass spectrometry. Rapid Commun. Mass Spectrom. 22(4), 477-485 (2008).
5. Thomas A, Kohler M, Schanzer W, Delahaut P, Thevis M. Determination of IGF-1 and IGF-2, their degradation products and synthetic analogues in urine by LC-MS/MS. Analyst 136(5), 1003-1012 (2011).
6. Powrie JK, Bassett EE, Rosen T et al. Detection of growth hormone abuse in sport. Growth Horm. IGF Res. 17(3), 220-226 (2007).
7. Pottgiesser T, Schumacher YO. Biomarker monitoring in sports doping control. Bioanalysis 4(10), 1245-1253 (2012).
8. Cox HD, Lopes F, Woldemariam GA et al. Interlaboratory agreement of insulin-like growth factor 1 concentrations measured by mass spectrometry. Clin. Chem. 60(3), 541-548 (2014).
9. Bystrom C, Sheng S, Zhang K, Caulfield M, Clarke NJ, Reitz R. Clinical utility of insulin-like growth factor 1 and 2; determination by high resolution mass spectrometry. PLoS ONE 7(9), e43457 (2012).
10. Cowan DA, Bartlett C. Laboratory issues in the implementation of the marker method. Growth Horm. IGF Res. 19(4), 357-360 (2009).
11. Cowans NJ, Suonpaa M, Kouru H, Wright D, Spencer K. Evaluation of a dried blood spot assay to measure prenatal screening markers pregnancy-associated plasma protein a and free beta-subunit of human chorionic gonadotropin. Clin. Chem. 59(6), 968-975 (2013).
12. Zimmermann MB, Moretti D, Chaouki N, Torresani T. Development of a dried whole-blood spot thyroglobulin assay and its evaluation as an indicator of thyroid status in goitrous children receiving iodized salt. Am. J. Clin. Nutr. 77(6), 1453-1458 (2003).
13. Hoffman BR, Yu H, Diamandis EP. Assay of prostatespecific antigen from whole blood spotted on filter paper and application to prostate cancer screening. Clin. Chem. 42(4), 536-544 (1996).
14. Chambers AG, Percy AJ, Yang J, Camenzind AG, Borchers CH. Multiplexed quantitation of endogenous proteins in dried blood spots by multiple reaction monitoring-mass spectrometry. Mol. Cell Proteomics 12(3), 781-791 (2013).
15. Sleczka BG, D'Arienzo CJ, Tymiak AA, Olah TV. Quantitation of therapeutic proteins following direct trypsin digestion of dried blood spot samples and detection by LC-MS-based bioanalytical methods in drug discovery. Bioanalysis 4(1), 29-40 (2012).
16. Kehler J, Akella N, Citerone D, Szapacs M. Application of DBS for the quantitative assessment of a protein biologic using on-card digestion LC-MS/MS or immunoassay. Bioanalysis 3(20), 2283-2290 (2011).
17. Dewilde A, Sadilkova K, Sadilek M, Vasta V, Hahn SH. Tryptic peptide analysis of ceruloplasmin in dried blood spots using liquid chromatography-tandem mass spectrometry: application to newborn screening. Clin. Chem. 54(12), 1961-1968 (2008).
18. Daniel YA, Turner C, Haynes RM, Hunt BJ, Dalton RN. Quantification of hemoglobin A2 by tandem mass spectrometry. Clin. Chem. 53(8), 1448-1454 (2007).
19. Chambers AG, Percy AJ, Hardie DB, Borchers CH. Comparison of proteins in whole blood and dried blood spot samples by LC/MS/MS. J. Am. Soc. Mass Spectrom. 24(9), 1338-1345 (2013).
20. Martin NJ, Bunch J, Cooper HJ. Dried blood spot proteomics: surface extraction of endogenous proteins coupled with automated sample preparation and mass spectrometry analysis. J. Am. Soc. Mass Spectrom. 24(8), 1242-1249 (2013).
21. De Kesel PM, Sadones N, Capiau S, Lambert WE, Stove CP. Hemato-critical issues in quantitative analysis of dried blood spots: challenges and solutions. Bioanalysis 5(16), 2023-2041 (2013).
22. Timmerman P, White S, Cobb Z, De Vries R, Thomas E, Van Baar B. Update of the EBF recommendation for the use of DBS in regulated bioanalysis integrating the conclusions from the EBF DBS-microsampling consortium. Bioanalysis 5(17), 2129-2136 (2013).
23. Wickremsinhe ER, Huang NH, Abdul BG, Knotts K, Ruterbories KJ, Manro JR. Preclinical bridging studies: understanding dried blood spot and plasma exposure profiles. Bioanalysis 5(2), 159-170 (2013).
24. De Vries R, Barfield M, Van De Merbel N et al. The effect of hematocrit on bioanalysis of DBS: results from the EBF DBS-microsampling consortium. Bioanalysis 5(17), 2147-2160 (2013).
25. Cox HD, Rampton J, Eichner D. Quantification of insulinlike growth factor-1 in dried blood spots for detection of growth hormone abuse in sport. Anal. Bioanal. Chem. 405(6), 1949-1958 (2013).
26. Agger SA, Marney LC, Hoofnagle AN. Simultaneous quantification of apolipoprotein A-I and apolipoprotein B by liquid-chromatography-multiple-reaction-monitoring mass spectrometry. Clin. Chem. 56(12), 1804-1813 (2010).
27. Percy AJ, Chambers AG, Smith DS, Borchers CH. Standardized protocols for quality control of MRM-based plasma proteomic workflows. J. Proteome Res. 12(1), 222-233 (2013).
28. Havlis J, Thomas H, Sebela M, Shevchenko A. Fast-response proteomics by accelerated in-gel digestion of proteins. Anal. Chem. 75(6), 1300-1306 (2003).
29. Altschul SF, Madden TL, Schaffer AA et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 25(17), 3389-3402 (1997).
30. Denniff P, Spooner N. The effect of hematocrit on assay bias when using DBS samples for the quantitative bioanalysis of drugs. Bioanalysis 2(8), 1385-1395 (2010).
31. Moller I, Thomas A, Geyer H, Schanzer W, Thevis M. Development and validation of a mass spectrometric detection method of peginesatide in dried blood spots for sports drug testing. Anal. Bioanal. Chem. 403(9), 2715-2724 (2012).
32. Youhnovski N, Bergeron A, Furtado M, Garofolo F. Pre-cut dried blood spot (PCDBS): an alternative to dried blood spot (DBS) technique to overcome hematocrit impact. Rapid Commun. Mass Spectrom. 25(19), 2951-2958 (2011).
33. Li Y, Henion J, Abbott R, Wang P. The use of a membrane filtration device to form dried plasma spots for the quantitative determination of guanfacine in whole blood. Rapid Commun. Mass Spectrom. 26(10), 1208-1212 (2012).